First device to identify dangerous stroke complication developed

by Mark Reynolds, Washington University in St. Louis

edited by Sadie Harley, reviewed by Andrew Zinin

Sadie Harley

Scientific Editor

Meet our editorial team
Behind our editorial process

Andrew Zinin

Chief Editor

Meet our editorial team
Behind our editorial process Editors' notes

This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

fact-checked

trusted source

proofread

The GIST Add as preferred source

An AI-enabled software tool that predicts the development of dangerous brain swelling after a stroke has received FDA Breakthrough Device designation. Beacon-Neuro.AI Inc., a Washington University in St. Louis startup, has gained access to technology underpinning the tool, which was developed by researchers at WashU Medicine.

The BeaconPredict software is the first device to predict malignant cerebral edema, a swelling of the brain that can occur in patients who have had an acute stroke. FDA Breakthrough Device designation is given to products that have been rigorously tested and are likely to advance treatment for acute or life-threatening conditions. The designation means that BeaconPredict will undergo an expedited approval process and receive FDA support to meet approval benchmarks.

Malignant cerebral edema affects up to 70,000 stroke patients in the U.S. each year and has a mortality rate of 80% if untreated. This swelling is the leading cause of death in the first week after a stroke. Studies have shown that interventions such as surgery are most effective within 48 hours of a stroke and can dramatically reduce the condition's mortality rate, but clinicians often wait until symptoms are apparent before intervening.

"Malignant cerebral edema is a major killer, but treatments are often not offered until after deterioration has already started, and that is driven by the fact that the available data and decision-making are not very accurate," said Rajat Dhar, a professor of neurology at WashU Medicine who founded Beacon-Neuro.AI and is the company's chief scientific and medical officer.

"BeaconPredict is taking the same data clinicians use and putting it through advanced AI to make that prediction more precise."

Specifically, BeaconPredict analyzes changes in brain scans taken in the first 24 hours after a patient is admitted to a hospital for stroke. This information is combined with the patient's blood pressure readings, age, neurological exam results and other data to generate a precise risk assessment of cerebral edema for the clinician.

Dhar said standard clinical approaches for assessing malignant cerebral edema have about a 70% accuracy rate in identifying patients in need of intervention.

In contrast, in a recent study, BeaconPredict was 99% accurate in identifying patients in need of surgery to relieve pressure in the brain 24 hours after a stroke, when tested on data from 598 stroke patients gathered from three medical centers.

Dhar said the system rarely mistook patients who did not need surgery as requiring intervention, achieving a precision rate of 87%—compared with 50% for current methods on the same measure.

Beacon-Neuro.AI, headquartered in Biogenerator Labs in St. Louis, was co-founded with Dhar earlier this year by Jin-Moo Lee, the Andrew B. and Gretchen P. Jones Professor of Neurology and head of the Department of Neurology at WashU Medicine, and Daniel Marcus, a professor of radiology at WashU Medicine Mallinckrodt Institute of Radiology.

"This Breakthrough Device designation is a testament to the value of researchers and clinicians at WashU Medicine being well-positioned to turn their discoveries into innovations that address pressing clinical needs," said Nichole Mercier, assistant vice chancellor and managing director of OTM.

"Dhar and his colleagues at Beacon-Neuro.AI drew on years of rigorous research and expertise from many different disciplines," added Mercier. "They had the imagination to tackle a previously intractable challenge in stroke care, and with the funding and support the university provides for advancing innovations like these, their entrepreneurial energy may well transform treatment for thousands of patients."

Key medical concepts

Acute Cerebrovascular Accident

Clinical categories

Neurology Provided by Washington University in St. Louis Who's behind this story?

Sadie Harley

BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →

Andrew Zinin

Master's in physics with research experience. Long-time science news enthusiast. Plays key role in Science X's editorial success. Full profile →

Citation: First device to identify dangerous stroke complication developed (2026, July 21) retrieved 21 July 2026 from https://medicalxpress.com/news/2026-07-device-dangerous-complication.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.